Study guide

7.2 Severe Asthma Exacerbation & COPD Acute Management

BCEMP Board Certified Emergency Medicine Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals

1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access

2 Chapter 2: Cardiac Arrest and Dysrhythmias

2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

3 Chapter 3: Shock and Hemodynamic Resuscitation

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols

4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation

5 Chapter 5: Neurocritical Care and Neurologic Emergencies

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies

6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure

7 Chapter 7: Pulmonary and Allergic Emergencies

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses

8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)

9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology

10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome

11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship

12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics

13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH

14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness

14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles

15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation

15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED

16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery

16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

18 Chapter 18: Special Populations, Medication Access, and Professional Practice

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)

7.2 Severe Asthma Exacerbation & COPD Acute Management

Key Takeaways Explain This Topic AI

In acute severe status asthmaticus, initial emergency management mandates combined inhaled short-acting beta-2 agonists (albuterol 10–15 mg/h continuous nebulization or 2.5–5 mg q20min x 3) and ipratropium bromide (0.5 mg nebulized q20min x 3 in hour 1), which synergistically reduces hospital admission rates.

Systemic corticosteroids (prednisone 40–60 mg PO or methylprednisolone 60–125 mg IV) must be initiated early; oral and IV routes provide identical clinical efficacy and time to recovery, reserving IV administration for patients with vomiting, severe dyspnea precluding swallowing, or mechanical ventilation.

Intravenous magnesium sulfate (2 g IV in 100 mL over 15–20 minutes) acts as a potent bronchial smooth muscle relaxant via voltage-gated calcium channel blockade and is indicated for severe life-threatening asthma (FEV1 or PEF <50%) or poor initial bronchodilator response.

Acute exacerbations of COPD (AECOPD) require controlled oxygen delivery targeting an SpO2 of 88% to 92% to prevent acute hypercapnic respiratory failure driven primarily by the reversal of hypoxic pulmonary vasoconstriction (V/Q mismatch) and the Haldane effect.

In AECOPD, the landmark REDUCE trial established that 5 days of oral prednisone (40 mg daily) is non-inferior to traditional 14-day courses, while 5-day antibiotic therapy is indicated for patients meeting Anthonisen criteria (increased sputum purulence plus dyspnea or volume) or requiring mechanical ventilation.

Last updated: October 2026

7.2 Severe Asthma Exacerbation & COPD Acute Management

Note

Independent BCEMP study resource provided by ExamFinch. Content covers Board of Pharmacy Specialties (BPS) Emergency Medicine Pharmacy examination topics.

Pathophysiology & Clinical Divergence: Asthma vs COPD

Acute obstructive airway emergencies represent two physiologically distinct pathological processes that converge on airflow limitation, ventilation-perfusion (V/Q) mismatch, dynamic air trapping, and respiratory muscle exhaustion.

Acute Status Asthmaticus : Driven by acute eosinophilic or allergic airway inflammation, intense smooth muscle bronchospasm, mucosal edema, and tenacious intraluminal mucus plugging. The underlying airway architecture is generally characterized by reversible bronchoconstriction, though severe attacks produce profound dynamic hyperinflation and intrinsic positive end-expiratory pressure (auto-PEEP).

Acute Exacerbation of COPD (AECOPD) : Driven by neutrophilic airway inflammation, loss of elastic parenchymal recoil (emphysema), chronic mucosal hypersecretion (chronic bronchitis), and baseline gas exchange impairment. Exacerbations are commonly triggered by viral or bacterial tracheobronchial infections, leading to dynamic expiratory collapse and acute-on-chronic carbon dioxide retention. ACUTE STATUS ASTHMATICUS RESUSCITATION

  • ┌───────────────────────────────────────────────────────────────────────────┐
  • │ HOUR 1 DUAL INHALED THERAPY │
  • │ • Albuterol: 10–15 mg/h continuous nebulization OR 2.5–5 mg q20min x 3 │
  • │ • Ipratropium Bromide: 0.5 mg nebulized q20min x 3 doses │
  • ├───────────────────────────────────────────────────────────────────────────┤
  • │ EARLY SYSTEMIC CORTICOSTEROIDS (Oral = IV Efficacy) │
  • │ • Prednisone 40–60 mg PO OR Methylprednisolone 60–125 mg IV │
  • │ • 4–6 hour genomic lag time; early administration halts hospital admission│
  • ├───────────────────────────────────────────────────────────────────────────┤
  • │ SECOND-LINE BRONCHODILATOR RESCUE (Severe / Refractory / PEF <50%) │
  • │ • Magnesium Sulfate: 2 g IV in 100 mL D5W/NS over 15–20 minutes │
  • │ • Terbutaline: 0.25 mg SC q20min x 3 OR Epinephrine: 0.3–0.5 mg IM │
  • ├───────────────────────────────────────────────────────────────────────────┤
  • │ PERI-INTUBATION INDUCTION & VENTILATION (Last Resort) │
  • │ • Ketamine 1–2 mg/kg IV (Direct bronchodilation via NMDA / catecholamines)│
  • │ • Ventilator: Low RR (8–10), small Vt (6 mL/kg), high peak flows (80 L/m)│
  • └───────────────────────────────────────────────────────────────────────────┘
  • Acute Status Asthmaticus: Inhaled Bronchodilator Protocols
  • Inhaled Short-Acting Beta-2 Agonists (SABA): Albuterol

Mechanism : Stimulates beta-2 adrenergic receptors on bronchial smooth muscle, activating adenylyl cyclase to increase intracellular cyclic AMP (cAMP). This activates protein kinase A, which decreases intracellular calcium concentrations, dephosphorylates myosin light chains, and produces profound smooth muscle relaxation.

Emergency Dosing :

Continuous Nebulization : 10 to 15 mg/hour continuously via a large-volume nebulizer. Indicated for severe respiratory distress, marked retractions, or peak expiratory flow (PEF) <50%.

Intermittent Nebulization : 2.5 to 5 mg every 20 minutes for 3 doses in the first hour, then 2.5 to 5 mg every 1 to 4 hours as needed.

Adverse Effects & Pharmacological Nuances :

Tachycardia & Tremor : Mediated by peripheral beta-2 vasodilation (causing reflex tachycardia) and skeletal muscle beta-2 stimulation.

Hypokalemia : Beta-2 receptor stimulation directly activates the Na⁺/K⁺-ATPase pump , driving potassium from the extracellular fluid into skeletal muscle cells. Serum potassium may drop by 0.5 to 1.0 mEq/L during continuous nebulization.

Type B Lactic Acidosis : High-dose albuterol stimulates hepatic and muscular glycogenolysis and lipolysis via beta-2 agonism, leading to accelerated aerobic glycolysis and excess pyruvate production, which is shunted to lactate. Clinicians must recognize that an isolated rising serum lactate with a stable or improving clinical exam represents drug-induced Type B lactic acidosis , rather than worsening tissue hypoxia or sepsis.

Inhaled Anticholinergics: Ipratropium Bromide

Mechanism : Quaternary ammonium antimuscarinic agent that competitively inhibits muscarinic M3 receptors on bronchial smooth muscle and submucosal glands, blocking parasympathetic vagal bronchoconstriction and reducing mucus hypersecretion.

Emergency Dosing : 0.5 mg nebulized every 20 minutes for 3 doses in the first hour, mixed directly with albuterol (e.g., DuoNeb).

Guideline Direction : Adding ipratropium to albuterol during the first hour of emergency management produces synergistic bronchodilation, significantly improves FEV1, and reduces hospital admission rates by approximately 30% in moderate-to-severe exacerbations. Beyond the initial 1 to 2 hours of emergency resuscitation, routine scheduled ipratropium provides minimal additional benefit in asthma and should be discontinued upon inpatient admission.

Systemic Corticosteroids: Oral vs Intravenous Equivalence

Systemic corticosteroids suppress airway inflammation, reduce microvascular permeability, decrease mucus production, and—most importantly—upregulate cell-surface beta-2 adrenergic receptor expression, reversing beta-agonist receptor downregulation and tachyphylaxis.

Route of Administration & Efficacy

Clinical Equivalence : Multiple randomized clinical trials and Cochrane systematic reviews have established that oral corticosteroids (Prednisone 40 to 60 mg PO) and intravenous corticosteroids (Methylprednisolone 60 to 125 mg IV) have identical clinical efficacy , rate of lung function recovery, and hospital length of stay.

Pharmacokinetics : Oral prednisone and prednisolone are rapidly and completely absorbed, with oral bioavailability approaching 80% to 90%. Serum concentrations peak within 1 to 2 hours.

Indications for IV Administration : The intravenous route should be strictly reserved for patients with active emesis, severe respiratory distress precluding the ability to swallow, altered mentation, or those requiring mechanical ventilation.

Genomic Lag Time : Corticosteroids act primarily via cytosolic glucocorticoid receptors to alter nuclear gene transcription (inhibiting NF-kB and upregulating anti-inflammatory lipocortin-1). This genomic mechanism requires a biological lag time of 4 to 6 hours before measurable clinical improvement occurs. Therefore, corticosteroids must be administered immediately upon ED triage to impact the disposition decision at hours 3 to 6.

Course Duration : 5 to 7 days in adults (3 to 5 days in pediatrics). Routine steroid tapering is unnecessary for courses lasting ≤7 to 10 days, as short courses do not produce clinically meaningful hypothalamic-pituitary-adrenal (HPA) axis suppression.

  • Second-Line Bronchodilator Therapies & Parenteral Beta-Agonists
  • Intravenous Magnesium Sulfate

Mechanism of Action : Magnesium acts as a physiological calcium antagonist. It blocks voltage-gated calcium channels on bronchial smooth muscle cells, inhibiting calcium influx required for actin-myosin cross-bridge cycling. Furthermore, it inhibits acetylcholine release at motor nerve terminals, blunts histamine release from mast cells, and stimulates prostacyclin and nitric oxide synthesis.

Dosing & Administration : 2 g IV (diluted in 100 mL 0.9% normal saline or 5% dextrose) infused over 15 to 20 minutes .

Clinical Indications : Indicated for patients with severe acute asthma who present with FEV1 or PEF <50% predicted , those who fail to demonstrate substantial clinical improvement after 1 hour of aggressive inhaled bronchodilator therapy, or those presenting in extremis.

Safety & Adverse Effects : Rapid infusion over <10 minutes can precipitate peripheral vasodilation, cutaneous flushing, transient hypotension, and bradycardia. True neuromuscular depression and hyporeflexia require serum magnesium concentrations >4 to 5 mEq/L, which are exceedingly rare with a single 2 g dose.

Parenteral Beta-Agonists: Terbutaline & Epinephrine

Terbutaline : Selective beta-2 agonist administered as 0.25 mg subcutaneously every 20 minutes for up to 3 doses. Useful in young patients when severe bronchospasm or high inspiratory resistance prevents aerosolized medication delivery.

Epinephrine : Administered as 0.3 to 0.5 mg IM (1 mg/mL / 1:1,000 solution) every 20 minutes for up to 3 doses. Preferred over terbutaline when acute asthma is triggered by an anaphylactic reaction or when severe dynamic hyperinflation completely limits inspiratory airflow.

Peri-Intubation Resuscitation & Mechanical Ventilation in Asthma

Endotracheal intubation in status asthmaticus is a life-threatening last resort associated with severe procedural complications, including pneumothorax, dynamic hyperinflation, circulatory collapse, and cardiac arrest.

Induction Pharmacology: The Primacy of Ketamine

Ketamine (1.5 to 2.0 mg/kg IV) is the induction agent of choice for rapid sequence intubation (RSI) in severe status asthmaticus.

Bronchodilatory Mechanisms : Ketamine produces potent, rapid bronchodilation through two distinct pathways:

Sympathomimetic Stimulation : Inhibits central and peripheral neuronal catecholamine reuptake, increasing circulating epinephrine and norepinephrine, which stimulate bronchial beta-2 receptors.

Direct Musculotropic Effect : Blocks L-type calcium channels and antagonizes N-methyl-D-aspartate (NMDA) receptors present on bronchial smooth muscle, directly attenuating airway tone.

Alternative Agents : Propofol (1.5 to 2.0 mg/kg IV) also exerts mild bronchodilatory properties but can cause profound systemic vasodilation and hypotension in volume-depleted, hyperinflated patients. Etomidate (0.3 mg/kg IV) is hemodynamically neutral but lacks bronchodilatory actions.

Neuromuscular Blockers : Rocuronium (1.2 mg/kg IV) or succinylcholine (1.5 mg/kg IV) should be selected. Older paralytics that provoke endogenous histamine release (e.g., atracurium, tubocurarine) are strictly contraindicated.

Mechanical Ventilator Strategy: Preventing Barotrauma

Patients with severe status asthmaticus have severe expiratory airflow obstruction requiring prolonged expiratory times to empty the lungs. Inadequate exhalation results in "breath stacking" and massive auto-PEEP (intrinsic PEEP) , which compresses the vena cava, obliterates right ventricular preload, and causes fatal PEA cardiac arrest.

Permissive Hypercapnia : The goal is not normal arterial blood gases, but preventing lung trauma. Clinicians should tolerate respiratory acidosis (pH ≥7.15 to 7.20, PaCO2 60 to 90 mmHg) to avoid excessive ventilation.

Ventilator Settings :

Low respiratory rate: 8 to 12 breaths/minute .

Small tidal volumes: 6 to 8 mL/kg predicted body weight .

High peak inspiratory flow rates: 70 to 80 L/minute (shortens inspiratory time, maximizing expiratory time).

Extended inspiratory-to-expiratory ratio: I:E ratio of 1:3, 1:4, or 1:5 .

Low external PEEP: 0 to 5 cm H2O (external PEEP must never exceed 80% of auto-PEEP).

Important

If an intubated asthma patient abruptly develops severe hypotension or PEA cardiac arrest, immediately disconnect the endotracheal tube from the ventilator circuit and forcefully compress the chest wall. This completely empties trapped air, eliminates auto-PEEP, and instantly restores venous return and cardiac output.

  • Acute Exacerbation of COPD (AECOPD) Resuscitation
  • Controlled Oxygen Delivery: Target SpO2 88% to 92%

Administering uncontrolled high-concentration supplemental oxygen (e.g., 100% via non-rebreather mask) to patients experiencing an acute COPD exacerbation can precipitate profound hypercapnia, severe respiratory acidosis, obtundation, and death. TRIPLE MECHANISMS OF O2-INDUCED HYPERCAPNIA

  • ┌───────────────────────────────────────────────────────────────────────────┐
  • │ 1. REVERSAL OF HYPOXIC PULMONARY VASOCONSTRICTION (HPV) [Dominant] │
  • │ High alveolar O2 dilates pulmonary arterioles supplying non-ventilated │
  • │ alveoli ──► Drastically increases dead space and V/Q mismatch │
  • ├───────────────────────────────────────────────────────────────────────────┤
  • │ 2. THE HALDANE EFFECT [Contributory] │
  • │ Deoxygenated hemoglobin binds CO2 with higher affinity than oxyhemoglobin│
  • │ Oxygenation displaces CO2 from carbaminohemoglobin into plasma ──► ↑PaCO2│
  • ├───────────────────────────────────────────────────────────────────────────┤
  • │ 3. BLUNTING OF HYPOXIC VENTILATORY DRIVE [Minor] │
  • │ Mild suppression of peripheral carotid chemoreceptor firing rate │
  • └───────────────────────────────────────────────────────────────────────────┘

Guidelines mandate controlled oxygen titration using a Venturi mask or low-flow nasal cannula targeting an arterial oxygen saturation (SpO2) of 88% to 92% (PaO2 ~60 to 70 mmHg).

Systemic Corticosteroids: The Landmark REDUCE Trial

The REDUCE Trial (2013) : The landmark Reduction in the Use of Corticosteroids in Exacerbated COPD (REDUCE) trial evaluated 314 patients presenting to the emergency department with acute COPD exacerbations, comparing 5 days of oral prednisone (40 mg daily) against the traditional 14 days of oral prednisone (40 mg daily) .

Findings : The 5-day regimen was completely non-inferior to the 14-day regimen regarding the rate of recurrent COPD exacerbation at 6 months (35.9% vs 36.8%), hospital length of stay, and all-cause mortality, while significantly reducing cumulative glucocorticoid exposure, secondary infections, and hyperglycemic adverse events.

Guideline Standard : GOLD guidelines endorse Prednisone 40 mg PO once daily for exactly 5 days as the gold standard for acute COPD exacerbations.

Antibiotic Indications: The Anthonisen Criteria

Bacterial tracheobronchial infections account for 50% to 70% of COPD exacerbations. Common pathogens include Haemophilus influenzae , Streptococcus pneumoniae , Moraxella catarrhalis , and, in patients with severe underlying disease, Pseudomonas aeruginosa .

Exacerbation Severity Anthonisen Cardinal Symptoms Present Antibiotic Indication

Type 1 (Severe) All 3 symptoms: (1) Increased Dyspnea, (2) Increased Sputum Volume, (3) Increased Sputum Purulence Strongly Indicated (Administer 5-day antimicrobial regimen)

Type 2 (Moderate) 2 symptoms: Must include Increased Sputum Purulence Indicated (Sputum purulence is the key predictor of bacterial infection)

Type 3 (Mild) 1 symptom + fever or URI within 5 days (Purulence absent) Not Indicated (Symptomatic and bronchodilator therapy only)

Ventilated AECOPD Any patient requiring non-invasive (BiPAP) or invasive mechanical ventilation Mandatory (Significantly reduces treatment failure and mortality)

Empirical Regimens (5-Day Duration) :

Azithromycin : 500 mg PO on day 1, then 250 mg PO daily on days 2 to 5.

Doxycycline : 100 mg PO twice daily for 5 days.

Amoxicillin-Clavulanate : 875/125 mg PO twice daily for 5 days.

Pseudomonas Risk (FEV1 <30%, frequent hospitalizations, chronic oral steroids): Ciprofloxacin 500 mg PO BID or Levofloxacin 500 mg PO daily for 5 to 7 days.

Non-Invasive Positive Pressure Ventilation (BiPAP)

Non-invasive positive pressure ventilation (BiPAP) is the first-line ventilatory support modality for acute hypercapnic respiratory failure (defined as respiratory acidosis: arterial pH <7.35 and PaCO2 >45 mmHg ).

Physiological Benefits : Inspiratory positive airway pressure (IPAP, 10 to 15 cm H2O) augments tidal volume and unloads fatigued diaphragmatic muscles, decreasing the work of breathing. Expiratory positive airway pressure (EPAP, 4 to 5 cm H2O) counteracts intrinsic auto-PEEP, recruits collapsed alveoli, and improves gas exchange.

Outcomes : BiPAP reduces endotracheal intubation rates by >60% and significantly lowers in-hospital mortality compared to standard medical therapy alone.